The price-to-earnings ratio for Halozyme Therapeutics Inc. (NASDAQ: HALO) is above average at 20.72x. The 36-month beta value for HALO is also noteworthy at 1.28. There are mixed opinions on the stock, with 5 analysts rating it as a “buy,” 2 rating it as “overweight,” 2 rating it as “hold,” and 0 rating it as “sell.”
The public float for HALO is 125.30M, and at present, short sellers hold a 7.87% of that float. The average trading volume of HALO on October 17, 2024 was 1.35M shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
HALO) stock’s latest price update
Halozyme Therapeutics Inc. (NASDAQ: HALO)’s stock price has plunge by -0.67relation to previous closing price of 53.82. Nevertheless, the company has seen a 5.53% surge in its stock price over the last five trading sessions. gurufocus.com reported 2024-10-08 that Wells Fargo has downgraded its rating for Halozyme Therapeutics (HALO, Financial), a U.S. biotechnology company, from “Overweight” to “Equal Weight,” with a target price set at $62, indicating limited upside potential. This year, Halozyme’s stock has surged by 50%, compared to the S&P 500’s approximately 21% rise.
HALO’s Market Performance
Halozyme Therapeutics Inc. (HALO) has seen a 5.53% rise in stock performance for the week, with a -13.68% decline in the past month and a -1.55% plunge in the past quarter. The volatility ratio for the week is 2.60%, and the volatility levels for the past 30 days are at 3.84% for HALO. The simple moving average for the last 20 days is -4.53% for HALO stock, with a simple moving average of 14.01% for the last 200 days.
Analysts’ Opinion of HALO
Many brokerage firms have already submitted their reports for HALO stocks, with Wells Fargo repeating the rating for HALO by listing it as a “Equal Weight.” The predicted price for HALO in the upcoming period, according to Wells Fargo is $62 based on the research report published on October 07, 2024 of the current year 2024.
JP Morgan, on the other hand, stated in their research note that they expect to see HALO reach a price target of $57, previously predicting the price at $52. The rating they have provided for HALO stocks is “Neutral” according to the report published on September 19th, 2024.
Piper Sandler gave a rating of “Neutral” to HALO, setting the target price at $51 in the report published on June 07th of the current year.
HALO Trading at -8.76% from the 50-Day Moving Average
After a stumble in the market that brought HALO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -18.42% of loss for the given period.
Volatility was left at 3.84%, however, over the last 30 days, the volatility rate increased by 2.60%, as shares sank -14.20% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +2.93% upper at present.
During the last 5 trading sessions, HALO rose by +5.53%, which changed the moving average for the period of 200-days by +44.64% in comparison to the 20-day moving average, which settled at $56.00. In addition, Halozyme Therapeutics Inc. saw 44.64% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at HALO starting from LaBarre Michael J., who sale 10,000 shares at the price of $53.75 back on Oct 15 ’24. After this action, LaBarre Michael J. now owns 173,756 shares of Halozyme Therapeutics Inc., valued at $537,469 using the latest closing price.
LaBarre Michael J., the SVP, CHIEF TECHNICAL OFFICER of Halozyme Therapeutics Inc., sale 10,000 shares at $53.26 during a trade that took place back on Oct 16 ’24, which means that LaBarre Michael J. is holding 173,756 shares at $532,590 based on the most recent closing price.
Stock Fundamentals for HALO
Current profitability levels for the company are sitting at:
- 0.46 for the present operating margin
- 0.76 for the gross margin
The net margin for Halozyme Therapeutics Inc. stands at 0.39. The total capital return value is set at 0.22. Equity return is now at value 153.16, with 17.85 for asset returns.
Based on Halozyme Therapeutics Inc. (HALO), the company’s capital structure generated 0.84 points at debt to capital in total, while cash flow to debt ratio is standing at 0.27. The debt to equity ratio resting at 5.3. The interest coverage ratio of the stock is 21.44.
Currently, EBITDA for the company is 422.43 million with net debt to EBITDA at 2.78. When we switch over and look at the enterprise to sales, we see a ratio of 9.3. The receivables turnover for the company is 4.07for trailing twelve months and the total asset turnover is 0.44. The liquidity ratio also appears to be rather interesting for investors as it stands at 7.41.
Conclusion
In summary, Halozyme Therapeutics Inc. (HALO) has had a mixed performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
